Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture  

作　　者：Chu-Xia Deng 

机构地区：[1]Cancer Center,Faculty of Health Sciences,University of Macao,Macao,P.R.China [2]MOE Frontier Science Center for Precision Oncology,University of Macao,Macao,P.R.China [3]Translational Research Center,Zhuhai UM Science&Technology Research Institute,Zhuhai,Guangdong,P.R.China

出　　处：《Cancer Communications》2024年第4期491-494,共4页癌症通讯（英文）

基　　金：Macao Science and Technology Development Fund,Grant/Award Number:0009/2022/AKP。

摘　　要：Immune checkpoint inhibitor(ICI)therapy has sig-nificantly revolutionized cancer treatment across vari-ous malignancies,offering distinct and enduring clin-ical advantages[1].Gastric cancer(GC)represents a widespread and life-threatening malignancy with substan-tial global health implications[2].However,ICI therapy has not produced satisfactory therapeutic responses in GC patients.

关 键 词：GASTRIC cancer IMMUNE 

分 类 号：R730.3[医药卫生—肿瘤]